124 related articles for article (PubMed ID: 10363692)
1. Captopril and platelet-activating factor (PAF) antagonist prevent cardiac allograft vasculopathy in rats: role of endogenous PAF and PAF-like compounds.
Crawford SE; Huang L; Hsueh W; Takami H; Gonzalez-Crussi F; Backer CL; Mu Y; Liu H; Mavroudis C
J Heart Lung Transplant; 1999 May; 18(5):470-7. PubMed ID: 10363692
[TBL] [Abstract][Full Text] [Related]
2. Captopril reduces graft coronary artery disease in a rat heterotopic transplant model.
Kobayashi J; Crawford SE; Backer CL; Zales VR; Takami H; Hsueh C; Huang L; Mavroudis C
Circulation; 1993 Nov; 88(5 Pt 2):II286-90. PubMed ID: 8222167
[TBL] [Abstract][Full Text] [Related]
3. Captopril suppresses post-transplantation angiogenic activity in rat allograft coronary vessels.
Crawford SE; Mavroudis C; Backer CL; Huang X; Mu Y; Volpert OV; Stellmach V; Pahl E; Huang L
J Heart Lung Transplant; 2004 Jun; 23(6):666-73. PubMed ID: 15366425
[TBL] [Abstract][Full Text] [Related]
4. Angiotensin II receptor antagonist TCV-116 reduces graft coronary artery disease and preserves graft status in a murine model. A comparative study with captopril.
Furukawa Y; Matsumori A; Hirozane T; Sasayama S
Circulation; 1996 Jan; 93(2):333-9. PubMed ID: 8548907
[TBL] [Abstract][Full Text] [Related]
5. Prolongation of rat heart allograft survival using low-dose cyclosporine and PAF antagonist WEB 2170.
Da Costa M; Metcalfe S; Calne RY
Transplant Proc; 1990 Aug; 22(4):1945-6. PubMed ID: 2389490
[No Abstract] [Full Text] [Related]
6. Platelet-activating factor and hyperacute rejection. The effect of a platelet-activating factor antagonist, SRI 63-441, on rejection of xenografts and allografts in sensitized hosts.
Makowka L; Chapman FA; Cramer DV; Qian SG; Sun H; Starzl TE
Transplantation; 1990 Sep; 50(3):359-65. PubMed ID: 2402783
[TBL] [Abstract][Full Text] [Related]
7. Anti-inflammatory effect of a PAF receptor antagonist and a new molecule with antiproteinase activity in an experimental model of acute urate crystal arthritis.
Miguélez R; Palacios I; Navarro F; Gutierrez S; Sanchez-Pernaute O; Egido J; González E; Herrero-Beaumont G
J Lipid Mediat Cell Signal; 1996 Jan; 13(1):35-49. PubMed ID: 8821809
[TBL] [Abstract][Full Text] [Related]
8. Beneficial effects of TCV-309, a novel potent and selective platelet activating factor antagonist in endotoxin and anaphylactic shock in rodents.
Terashita Z; Kawamura M; Takatani M; Tsushima S; Imura Y; Nishikawa K
J Pharmacol Exp Ther; 1992 Feb; 260(2):748-55. PubMed ID: 1738121
[TBL] [Abstract][Full Text] [Related]
9. [The roles of platelet activating factor in intestinal mucosal barrier injury after burn].
Yu P; Xiao G; Fu W
Zhonghua Wai Ke Za Zhi; 1995 Jul; 33(7):393-5. PubMed ID: 8565724
[TBL] [Abstract][Full Text] [Related]
10. TCV-116 reduces chronic rejection in a rat heterotopic cardiac transplant model.
Richter M; Westphal M; Maybaum B; Richter H; Skupin M; Mohr FW; Olbrich HG
Transplant Proc; 1999; 31(1-2):106-7. PubMed ID: 10083031
[No Abstract] [Full Text] [Related]
11. An intravascular ultrasound study of the influence of angiotensin-converting enzyme inhibitors and calcium entry blockers on the development of cardiac allograft vasculopathy.
Mehra MR; Ventura HO; Smart FW; Collins TJ; Ramee SR; Stapleton DD
Am J Cardiol; 1995 Apr; 75(12):853-4. PubMed ID: 7717300
[No Abstract] [Full Text] [Related]
12. Continuous binding of the PAF molecule to its receptor is necessary for the long-term aggregation of platelets.
Suzuki M; Sugatani J; Ino M; Shimura M; Akiyama M; Yamazaki R; Suzuki Y; Miwa M
Am J Physiol; 1998 Jan; 274(1):C47-57. PubMed ID: 9458712
[TBL] [Abstract][Full Text] [Related]
13. Role of platelet activating factor in kidney transplant rejection in the rat.
Butterly DW; Spurney RF; Ruiz P; Pirotzky E; Braquet P; Coffman TM
Kidney Int; 1995 Aug; 48(2):337-43. PubMed ID: 7564100
[TBL] [Abstract][Full Text] [Related]
14. Evidence that phospholipid oxidation products and/or platelet-activating factor play an important role in early atherogenesis : in vitro and In vivo inhibition by WEB 2086.
Subbanagounder G; Leitinger N; Shih PT; Faull KF; Berliner JA
Circ Res; 1999 Aug; 85(4):311-8. PubMed ID: 10455059
[TBL] [Abstract][Full Text] [Related]
15. Sinomenine blocks tissue remodeling in a rat model of chronic cardiac allograft rejection.
Mark W; Schneeberger S; Seiler R; Stroka DM; Amberger A; Offner F; Candinas D; Margreiter R
Transplantation; 2003 Apr; 75(7):940-5. PubMed ID: 12698077
[TBL] [Abstract][Full Text] [Related]
16. Experimental cardiac allograft vasculopathy in mice.
Ardehali A; Billingsley A; Laks H; Drinkwater DC; Sorensen TJ; Drake TA
J Heart Lung Transplant; 1993; 12(5):730-5. PubMed ID: 8241210
[TBL] [Abstract][Full Text] [Related]
17. Prolonged rat heart allograft survival after treatment with angiotensin converting enzyme inhibitor or a calcium antagonist.
Mjörnstedt L; Lukes D; Arvidsson N; Herlitz H; Olausson M
Scand J Urol Nephrol; 1998 Sep; 32(5):341-4. PubMed ID: 9825397
[TBL] [Abstract][Full Text] [Related]
18. A Penicillium sp. F33 metabolite and its synthetic derivatives inhibit acetyl-CoA:1-O-alkyl-sn-glycero-3-phosphocholine acetyltransferase (a key enzyme in platelet-activating factor biosynthesis) and carrageenan-induced paw edema in mice.
Yamazaki Y; Yasuda K; Matsuyama T; Ishihara T; Higa R; Sawairi T; Yamaguchi M; Egi M; Akai S; Miyase T; Ikari A; Miwa M; Sugatani J
Biochem Pharmacol; 2013 Sep; 86(5):632-44. PubMed ID: 23817078
[TBL] [Abstract][Full Text] [Related]
19. Platelet activating factor (PAF) antagonists on cytokine induction of iNOS and sPLA2 in immortalized astrocytes (DITNC).
Wang JH; Sun GY
Neurochem Res; 2000 May; 25(5):613-9. PubMed ID: 10905622
[TBL] [Abstract][Full Text] [Related]
20. [PAF receptor antagonist in asthma therapy].
Sagara H; Makino S; Fukuda T
Nihon Rinsho; 1996 Nov; 54(11):3056-61. PubMed ID: 8950954
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
